Insulin icodec for treating type 2 diabetes [ID6175]

Suggested remit: To appraise the clinical and cost effectiveness of insulin icodec within its marketing authorisation for treating type 2 diabetes.

Following an update from the company (Novo Nordisk), NICE have suspended this appraisal from its current work programme until further notice. NICE will continue to monitor the situation and will provide an update when further information becomes available.

Status:

Suspended

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6175

Project Team

Project lead

Leena Issa

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

Bristol Technology Assessment Group, University of Bristol

Stakeholders

Companies sponsors

Novo Nordisk (insulin icodec)

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

None

Professional groups

Royal College of Physicians

 

UK Clinical Pharmacy Association

Associated public health groups

None

Comparator companies

A. Menarini Farmaceutica Internazionale (canagliflozin, metformin) (confidentiality agreement not signed, not participating)

 

AstraZeneca (exenatide, dapagliflozin, metformin, saxagliptin) (confidentiality agreement signed, participating)

 

Aurobindo Pharma (gliclazide, metformin, sitagliptin, vildagliptin) (confidentiality agreement not signed, not participating)

 

Bioproject (glibenclamide) (confidentiality agreement not signed, not participating)

 

Boehringer Ingelheim (empagliflozin, linagliptin, metformin) (confidentiality agreement not signed, not participating)

 

Bristol laboratories (gliclazide) (confidentiality agreement not signed, not participating)

 

Brown and Burk UK (gliclazide, glimepiride, metformin, pioglitazone) (confidentiality agreement not signed, not participating)

 

Celix Pharma (metformin, sitagliptin) (confidentiality agreement not signed, not participating)

 

Colonis Pharma (metformin) (confidentiality agreement not signed, not participating)

 

Dr Reddy’s Laboratories (metformin, sitagliptin) (confidentiality agreement not signed, not participating)

 

Eli Lilly (dulaglutide, insulin, tirzepatide) (confidentiality agreement signed, participating)

 

Flamingo Pharma (gliclazide) (confidentiality agreement not signed, not participating)

 

Genus Pharmaceuticals (metformin, sitagliptin) (confidentiality agreement not signed, not participating)

 

Glenmark Pharmaceuticals (metformin, sitagliptin) (confidentiality agreement not signed, not participating)

 

Ipca Laboratories (metformin) (confidentiality agreement not signed, not participating)

 

Krka UK (gliclazide, sitagliptin) (confidentiality agreement not signed, not participating)

 

Lupin Healthcare (gliclazide) (confidentiality agreement not signed, not participating)

 

Morningside Healthcare (metformin) (confidentiality agreement not signed, not participating)

 

MSD (ertugliflozin, metformin, sitagliptin) (confidentiality agreement not signed, not participating)

 

Mylan (gliclazide, insulin, pioglitazone, sitagliptin) (confidentiality agreement not signed, not participating)

 

Neon Healthcare (metformin, pioglitazone) (confidentiality agreement not signed, not participating)

 

Novartis (metformin, vildagliptin) (confidentiality agreement not signed, not participating)

 

Novo Nordisk (insulin, liraglutide, semaglutide) (confidentiality agreement not signed, not participating)

 

Pfizer (glipizide) (confidentiality agreement not signed, not participating)

 

Pinewood Healthcare (metformin) (confidentiality agreement not signed, not participating)

 

Rosemont Pharmaceuticals (metformin) (confidentiality agreement not signed, not participating)

 

Sandoz (metformin, pioglitazone) (confidentiality agreement not signed, not participating)

 

Sanofi (insulin, lixisenatide) (confidentiality agreement not signed, not participating)

 

Servier Laboratories (gliclazide) (confidentiality agreement not signed, not participating)

 

Sigma Pharmaceuticals (metformin) (confidentiality agreement not signed, not participating)

 

Sovereign Medical (tolbutamide) (confidentiality agreement not signed, not participating)

 

Strides Pharma (metformin) (confidentiality agreement not signed, not participating)

 

Sun Pharmaceuticals (sitagliptin) (confidentiality agreement not signed, not participating)

 

Takeda (alogliptin, metformin) (confidentiality agreement not signed, not participating)

 

Thame Laboratories (metformin, sitagliptin) (confidentiality agreement not signed, not participating)

 

Tillomed Laboratories (metformin) (confidentiality agreement not signed, not participating)

 

Wockhardt (metformin) (confidentiality agreement not signed, not participating)

 

Zentiva (gliclazide, metformin, sitagliptin) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health - Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

Scottish Medicines Consortium

 

Welsh Government

 

Welsh Health Specialised Services Committee

Relevant research groups

None

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual